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Abstract
The X-linked RP3 gene codes for the ciliary protein RPGR and accounts for over 10% of inherited 
retinal degenerations. The critical RPGR-ORF15 splice variant contains a highly repetitive purine-
rich linker region that renders it unstable and difficult to adapt for gene therapy. To test the 
hypothesis that the precise length of the linker region is not critical for function, we evaluated 
whether AAV-mediated replacement gene therapy with a human ORF15 variant containing in-
frame shortening of the linker region could reconstitute RPGR function in vivo. We delivered 
human RPGR-ORF15 replacement genes with deletion of most (314-codons, “short form”) or 1/3 
(126-codons, “long form”) of the linker region to Rpgr null mice. Human RPGR-ORF15 
expression was detected post-treatment with both forms of ORF15 transgenes. However, only the 
long form correctly localized to the connecting cilia and led to significant functional and 
morphological rescue of rods and cones. Thus the highly repetitive region of RPGR is functionally 
important but that moderate shortening of its length, which confers the advantage of added 
stability, preserves its function. These findings provide a theoretical basis for optimizing 
replacement gene design in clinical trials for X-linked RP3.
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Introduction
Retinitis pigmentosa (RP) is a leading form of inherited blindness in humans, with three 
general modes of inheritance (autosomal dominant, autosomal recessive, and X-linked). 
Over 70% of X-linked RP (and up to 20% of all RP cases) are caused by mutations in the 
gene encoding retinitis pigmentosa GTPase regulator (RPGR)1-4, which involves both rod 
and cone photoreceptors as primary targets5 and particularly impacts central vision6. Its high 
frequency and associated central visual handicap make RPGR an important RP disease gene.
RPGR is expressed in a complex pattern, with both default and ORF15 variants having been 
described7. The default or constitutive form of RPGR spans exons 1-19 and ORF15 
terminates in a large alternative exon designated ORF15 excluding exons 16-19. The ORF15 
exon is unique in that it contains a long purine rich repetitive sequence that proved 
impossible to clone into cDNA from retinal RNA and unstable in many procedures of 
recombinant DNA manipulations. The repetitive region is highly charged with a large 
number of glutamic acid residues and serves as a linker connecting the conserved N-terminal 
RCC1 homology domain and a C-terminal domain with no known functional motifs. While 
the smaller default form of RPGR is the predominant form in most tissues with primary or 
motile cilia8, the ORF15 isoform of RPGR is necessary for normal rod and cone function in 
the retina7, 9 and is expressed primarily in photoreceptors8. The ORF15 region is a mutation 
hotspot in RPGR, with mutations identified in this region in up to 60% of patients with X-
linked RP7, 10, 11.
We developed the first mouse model of X-linked RP carrying a null mutation in Rpgr with 
no detectable levels of any isoforms of RPGR5. Rpgr null mice manifest a slowly 
progressive retinal degeneration that is characterized by early cone opsin mislocalization in 
cell bodies and synapses and reduced levels of rhodopsin in rods. By 12 months of age 
significant photoreceptor cell loss and decline in cone and rod function, as measured by 
electroretinograms (ERG), become apparent. In the retina, RPGR is bound to the 
photoreceptor connecting cilium via an RPGR interacting protein (RPGRIP1)12-14. The 
connecting cilium is analogous to the transition zone of motile or primary cilia that serves as 
a gateway for protein trafficking to the outer segment. This subcellular localization pattern 
and the mutant mouse phenotype suggest that RPGR may have a role in protein trafficking 
between the inner and outer segment of both rods and cones5, 14, 15. In attempts to develop 
an Rpgr mutant mouse model with a faster course of degeneration, several other Rpgr mouse 
lines have been recently developed16, 17. There has also been a recent report of a naturally 
occurring model (rd9) of X-linked Rpgr18. In all of these cases, including the Rpgr null, 
mice display a slowly progressive loss of photoreceptors and varying degree of rod and cone 
involvement that may be due, in part, to differences in strain and/or pigmentation. These 
findings indicate that the slow rate of degeneration in the knockout model is due to species 
differences rather than the ablation being incomplete, and support the applicability of this 
murine model in therapeutic studies of null RPGR mutations in patients.
We have previously demonstrated functional and morphological rescue of both rod and cone 
photoreceptor cells in mice lacking RPGR using an abbreviated murine Rpgr ORF15 
isoform and a transgenic approach19. The rationale for the abbreviated construct was two 
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fold. First, the abbreviated construct could be amplified by RT-PCR from mouse retina 
mRNA, whereas the published “full-length” form of Rpgr ORF15 was not and therefore, 
was never verified as being actually present in nature. Second, the purine-rich repetitive 
linker region in the ORF15 15 exon rendered the sequence unstable and hence prone to 
spontaneous deletions or rearrangements that could generate disease-causing frame shift 
mutations (unpublished observations). Since variation in the length of the repetitive region is 
frequently found in normal individuals1, 20, 21, the precise length of the repetitive region 
appears not to be critical for function. Our previous mouse study using a murine Rpgr 
ORF15 that is shortened by one third in the linker region supports this notion19. Therefore, 
an argument could be made that trading off some length (in-frame) of this region for added 
stability may be of net benefit because it generates a safer and still efficacious replacement 
gene construct. These considerations prompted us to explore this idea further. In the present 
study, we tested if a shortened human RPGR ORF15 replacement gene, driven by our 
previously characterized rhodopsin kinase (RK) promoter22, 23 and delivered in the AAV8 
vector that expresses transgenes faster and displays favorable tropism toward 
photoreceptors24, 25, would rescue photoreceptor degeneration in the Rpgr null mice. The 
results of the study shows that the purine-rich repetitive region of ORF15 exon is required 
for correct subcellular localization and full function of RPGR, but that moderate shortening 
of its length is well tolerated. These data lend credence to the proposal that a shortened 
RPGR ORF15 replacement gene may offer a viable alternative to the thus far elusive “full-
length” RPGR ORF15 in future human gene therapy trials.
Results
AAV-mediated expression of human RPGR ORF15
We constructed two human RPGR ORF15 replacement genes, one with an in-frame deletion 
of 126 codons (long form, ORF15-L) and the other with an in-frame deletion of 314 codons 
(short form, ORF15-S). Both were inserted into an AAV8 vector under the control of a 
human rhodopsin kinase promoter (Fig. 1A) 22, 23. Subretinal delivery of the two human 
RPGR ORF15 replacement genes led to the production of recombinant RPGR protein. By 
western blotting, 2 weeks following AAV vector administration, ORF15-L appeared as an ~ 
160-kD protein while ORF15-S produced an ~ 130-kD protein. Both protein products were 
smaller than endogenous human ORF15 seen in human retinal extract (~ 200 kD) (Figs. 1B). 
Both forms of replacement ORF15 appeared as a single band when probed with an antibody 
against the C-terminus of human RPGR. Under our experimental conditions and the dosages 
given, the expression levels of ORF15-S and ORF15-L were comparable.
Both forms of ORF15 could be seen in the retina of Rpgr−/− mice by immunofluorescence 
staining of unfixed cryosections (3 weeks following subretinal injections). ORF15-L 
correctly localized to a narrow band in between the inner and outer segments where the 
connecting cilia reside. However, ORF15-S gave much weaker signals at the CC (Fig. 2A) 
than ORF15-L. In well-transduced retinal areas the signal from ORF15-L treated retinas 
appeared indistinguishable from the WT signal (Fig. 2A, B). Double-labeling with an 
antibody for the ciliary rootlets, which originate from the proximal ends of basal bodies and 
extend toward the cell interior and thus serve as a marker for the ciliary region 8, 26, 
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confirmed the correct subcellular localization of the recombinant RPGR to the connecting 
cilia (Fig. 2B). In contrast to the robust protein expression determined by western blotting, 
only ORF15-L appeared to have a robust signal in every CC matching the number of 
rootlets, whereas ORF15-S treated retinas, many rootlets did not have an RPGR signal at 
their distal ends. Figure 2C shows a bar graph representing RPGR label counts relative to the 
counts of rooteletin fibers in Rpgr −/− mouse retinas treated with either the long or short 
form of human ORF15 as well as in untreated wildtype mouse retinas. There was no 
difference in the mean ratios (RPGR signal count divided by Rootletin fiber count) for the 
ORF15 long form versus the wild type (Dunnett's method, p = .24) but a significantly lower 
mean ratio for the ORF15 short form versus the wildtype (p = .0019). Given the somewhat 
similar level of expression by immunoblotting, this disparity in protein localization at the 
connecting cilium suggested a somewhat reduced affinity of ORF15-S for the CC. Further 
analysis by immunostaining of fixed retinal sections, which afforded better preservation of 
tissues at the expense of signal strength at the CC, revealed a pattern of ORF15-S 
mislocalized to photoreceptor inner and outer segments (Fig. 2D). No mislocalization was 
seen for ORF15-L, which had a staining pattern similar to WT. Thus, the lack of staining for 
the short form RPGR at the CC was due to a reduced ability to localize to this subcellular 
compartment, rather than a lower level of expression overall.
Human ORF15-L expression in Rpgr null mice promotes rod and cone survival
To investigate a therapeutic efficacy of the two replacement genes, we evaluated Rpgr−/− 
mouse photoreceptors by immunostaining to look for signs of improvement in rod and cone 
morphology. By 13 months of age (6 months post treatment), both control and ORF15-S 
treated eyes had the typical degenerative appearance for this age (Fig. 3). Rod and cone 
outer segments were shortened and disorganized compared to WT eyes, with rod opsin 
mislocalization seen throughout the outer nuclear layer and cone opsin mislocalization in the 
synaptic layer. The outer nuclear layer was also comparably reduced in thickness in control 
and ORF15-S treated eyes. In contrast, eyes treated with ORF15-L had rhodopsin expression 
in rods that was properly partitioned to the outer segments with no obvious signs of 
mislocalization. Similarly, cone photoreceptor survival was enhanced following treatment 
with the longer ORF15 construct, with rare cone opsin mislocalization. In addition, ORF15-
L treated eyes were found to have more cells (with nearly normal-appearing rod and cone 
outer segments) than control or ORF15-S treated eyes. Based on these findings longitudinal 
studies were carried out in mice treated with ORF15-L.
We measured the thickness of the outer nuclear layer (ONL) and the length of photoreceptor 
inner/outer segments in both eyes of 3 Rpgr−/− mice. These were measured in 3 regions of 
the superior hemisphere and in 3 regions of the inferior hemisphere, each region separated 
by 600μm and beginning 600 μm to either side of the optic nerve head along the vertical 
meridian. Repeated-measures full-factorial regression at ages 11 months and 18 months was 
used to identify differences by eye, hemisphere, and region as main effects, as well as their 
cross-products to determine whether a treatment effect varied geographically. At 11 months 
of age, ONL thickness was normally distributed but inner segment/outer segment length was 
not (Shapiro-Wilk W goodness of fit test, p = .016); at 18 months of age, neither ONL 
thickness nor inner segment/outer segment length was normally distributed (p = .0011 and p 
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= .0002, respectively). At 11 months of age, mean ONL thickness was significantly greater 
for treated eyes (48.0 μm) than for control eyes (38.0 μm, p = .0015); mean inner segment/
outer segment length was also significantly greater for treated eyes (45.1 μm) than for 
control eyes (29.5 μm, p < .0001, p < .0001 for normalized ranks). No other effect was 
statistically significant. At 18 months of age the differences in retinal morphology between 
fellow eyes were even more marked: mean ONL thickness was 22.8 μm for treated eyes and 
13.7 μm for control eyes (p < .0001, p < .0001 for normalized ranks), while mean inner 
segment/outer segment length was 19.8 μm for treated eyes and 7.3 μm for control eyes (p 
< .0001, p < .0001 for normalized ranks). At this age we initially observed that the treatment 
benefit for IS/OS length was significantly greater in the superior retina than in the inferior 
retina at 18 months (p = .0036), but this did not hold up after converting length to 
normalized ranks (p = .17). Figure 4A illustrates ONL thickness and IS/OS length by region 
for treated and control eyes at 18 months of age.
Figure 4B shows representative light micrographs taken from a representative ORF15-L 
treated and fellow control eye at 18 months of age. In the control retina, the best-preserved 
area has only about 2-3 rows of loosely arranged photoreceptor nuclei with shortened and 
disorganized photoreceptor inner/outer segments. Note that the margins of the inner and 
outer segments are no longer distinct. The treated retina, on the other hand, has about 5-6 
rows of photoreceptor cells throughout, with longer, better organized, and distinct inner and 
outer segments.
Human RPGR ORF15-L expression improves rod and cone function
Retinal function as monitored by full-field rod and cone ERGs was evaluated in a cohort 
(n=22) of Rpgr−/− mice from 9-months to 18-months of age. Mice received treatment 
between 3 and 7 months of age, and follow-up ERGs were recorded no sooner than 6-
months following injection. Figure 5A shows rod and cone ERG amplitudes by eye for 16 
mice tested between 11 and 14 months of age. Control eyes (OD) showed disproportionate 
loss of cone b-wave amplitude relative to rod b-wave amplitude compared with the lower 
limits for wild-type mice, as previously observed in this murine model of RPGR−/− mice 
(Hong and others, 2000) and evidence for a cone-rod degeneration. In every case but one, 
the treated eye (OS) had a larger a-wave and b-wave amplitude compared with the fellow 
control eye (OD), demonstrating improvement of rod and cone photoreceptor function. In 
fact, 56% of the treated eyes (9/16) had rod b-wave amplitudes that were at or above the 
lower limit of age-matched WT values (dotted line). Geometric mean values for rod ERG a-
wave and b-wave amplitude were 121 μV OS and 65 μV OD for the a-wave and 482 μV OS 
and 267 μV OD for the b-wave. Mean cone ERG b-wave amplitudes were 22 μV OS and 11 
μV OD. These data show an 81-86% improvement of rod function and a 100% improvement 
of cone function with AAV- ORF15-L treatment for this age range.
In the full cohort of 22 mice, we used repeated measures longitudinal regression to compare 
rates of change for log rod and cone b-wave amplitudes by eye (Fig. 5B). Estimated 
exponential mean rates of decline for rod b-wave amplitude were 8.6%/month in the control 
eyes and 3.8%/month in the treated eyes; the difference between these two means was 
significant (p=0.0001). Estimated exponential mean rates of decline for cone b-wave 
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amplitude were 5.8%/month in the control eyes and 0.8%/month in the treated eyes; the 
difference between these two means was also significant (p<0.0001), and the decline in cone 
b-wave amplitude in the treated eyes was not significantly different from zero (p = 0.54) — 
indicating no observable progression or loss in cone function over this period.
Representative rod and cone ERGs are shown in figure 5C to illustrate waveforms in treated 
and control eyes, including a WT, at 18 months of age (the final time point). In control eyes 
rod function was reduced, on average by 75%, while cone function was minimal and in some 
cases non-detectable. In contrast, treated eyes retained substantial, though subnormal, rod 
and cone function.
Discussion
In the present study Rpgr null mice treated with human RPGR ORF15-L showed significant 
rescue of cone and rod photoreceptor cells and function. Remarkably, treated mice had 
stable cone function between 9 and 18 months of age. This is a particularly desirable 
outcome for potential application to patients with X-linked RP due to mutations in RPGR, 
especially those affecting exon 15 of the protein that can cause cone-rod degeneration (see 
supplemental data) 27,28. Thus the ORF15-L variant appears functional and may have future 
application in translation to the clinic. Since rescue in Rpgr null mice in the present study 
following treatment was nonetheless incomplete, it remains possible that a full-length 
version of RPGR ORF15 may lead to even better rescue. However, we do not believe that is 
necessarily the case, since all gene therapy attempts thus far, even under the most optimized 
conditions, have led to incomplete rescue. It is more likely that issues relating to vector gene 
transduction, percentage coverage of the retina, gene expression levels and age or stage of 
disease of intervention provide more plausible explanations for incomplete rescue as well as 
avenues for improving the therapeutic benefits of RPGR gene augmentation. Still, it should 
be pointed out that the level of remaining retinal function in our mice treated with the 
abbreviated human RPGR ORF15-L would be consonant with their retaining normal, or 
nearly normal, visual fields to a large test light and, therefore, considerable mobility — 
based on the relationship between visual field size and ERG amplitude in RP patients 29.
Viral vector-mediated somatic gene therapy has shown great promise in treating animal 
models of human retinal degenerative disease. To date, there have been a number of 
successful studies using adeno-associated virus (AAV)-mediated gene delivery to rescue 
photoreceptor degeneration in rodent models 30-34 and in larger animal models 35-39. In 
addition, Phase I clinical trials involving gene therapy for patients with Leber Congenital 
Amaurosis (LCA) targeting the RPE 40-42 and more recently choroideremia 43 have already 
met with some success. Mutations in RPGR are one of the most common causes of all forms 
of retinitis pigmentosa 4 and are associated with a more severe loss of central vision than 
most other genotypes. Hence RPGR is of great interest as a target for gene therapy 
development. There have been two reports of using full-length human RPGR ORF15 for 
replacement gene therapies in the canine and mouse models of X-linked RP37, 44. There are 
currently no clinical trials using AAV-mediated gene replacement therapy for the treatment 
of patients with X-linked RP, but such trials are likely to be underway in the near future.
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For a successful implementation of RPGR replacement gene therapy, a number of issues 
need to be considered. First, RPGR is required for both rod and cone survival. Therefore, the 
replacement gene expression needs to be driven by a cell type specific promoter that is active 
in rods and cones, but not in RPE cells. The RK promoter used in this study appears to fulfill 
this requirement. A similar RK promoter design has been previously shown to drive gene 
expression efficiently in both rod and cone photoreceptors 22. In the present study, robust 
protein expression was seen for both abbreviated forms of RPGR ORF15 as evidenced by 
IHC and Western blotting data. By Western blotting both forms of ORF15 were expressed at 
levels that were similar to or slightly above that seen in a normal human retina. By 
immunofluorescence, both forms of ORF15 were found exclusively in the photoreceptor 
cells, and absent in the RPE or the inner retina. Thus the replacement gene constructs used 
in this study were able to drive expression in the target cells and at levels that are likely 
appropriate for therapeutic studies. The combination of the fast acting AAV8 delivery vector 
and our human RK promoter has been previously used to rescue photoreceptor degeneration 
in two murine models of Leber congenital amaurosis (AIPL1 and RPGRIP1) 23, 31, 33. This 
strategy is likely to be useful in future clinical studies for RPGR gene replacement.
The second issue is the choice of the replacement gene sequence that is to be incorporated 
into the vector construct. More often than not, multiple transcript variants will be expressed 
from a single gene due to alternative splicing or transcriptional start and termination. 
Alternative splicing underlies the evolution of increased proteomic and functional 
complexity and is especially prevalent in neural tissues. For RPGR, this issue is particularly 
acute because of its complex expression patterns. It is now widely accepted that the ORF15 
variant is the functional important isoform in photoreceptors and should be the choice for 
any gene therapy attempt. However, the ORF15 variant of RPGR contains a long stretch of 
highly repetitive, purine-rich region that makes it difficult to be reverse transcribed into 
cDNA and prone to deletions and rearrangements during plasmid propagation. These same 
traits probably render it a mutation hot spot in humans. Thus the stability of the ORF15 
region is a concern for human RPGR gene therapy. It remains unclear why the ORF15 
region is so unstable or difficult to clone. Analysis of this region shows that the purine-rich 
sequence has a strong potential for forming multiple, stable G-quadruplexes. Such secondary 
structures will likely interfere with reverse transcription and DNA replication. The repetitive 
nature of the sequence may also lead to polymerase slippage thus compromising fidelity of 
DNA replication. In a previous study with murine ORF15 19 a moderate in-frame shortening 
of this region (by 650 bp of nearly one half of the repetitive region in mouse RPGR ORF15) 
was shown to increase the stability of the cDNA. RPGR protein product from this 
abbreviated construct localized correctly to the photoreceptor connecting cilia and rescued 
the disease phenotype. Thus this shortened form of RPGR retained its function. In the 
current study, we delivered a human ORF15 that was shortened by about one third in the 
purine rich repetitive region, and found it to correctly localize to the connecting cilia of 
photoreceptors and rescue the disease phenotype. These findings show that the ORF15-L 
form of RPGR described in this study retains RPGR function in vivo. In contrast, the 
ORF15-S form had lost most of the purine rich region, and was found unable to localize to 
the connecting cilia efficiently and failed to rescue the disease phenotype. Thus, while 
shortening of the purine rich region by about one third may promote photoreceptor rescue in 
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patients with RPGR mutations, further reduction in the length of this region would not be 
expected to lead to this benefit. The conclusion that abbreviated RPGR could remain 
functional is also supported by other circumstantial evidence. First, there is considerable 
variation in the length of this region, albeit only by dozens of base pairs, among normal 
human retinas. Second, different mammalian species vary considerably in the length of this 
region. For example, this region is longer by about 200 base pairs in mice compared to 
humans. In comparison, the length of the RCC1 homology domain in the N terminal half of 
the protein, and the C terminal unique region are very similar between the species. Our data 
therefore provide a useful guideline on the design of an abbreviated human RPGR ORF15 
replacement gene for future clinical studies that affords both the benefit of increased stability 
and functionality.
The idea of using abbreviated genes for gene therapy is by no means a novel one. This 
strategy is currently being used in clinical trials to deliver a miniaturized version in lieu of 
the full-length dystrophin gene (14 kb) by AAV vectors, which have a packaging limit of 
about 4.7 kb, to patients afflicted with X-linked Duchenne muscular dystrophy. In the case 
of RPGR, the motivation for studying shortened versions is different. The full-length RPGR 
ORF15 gene should have no difficulty fitting into existing AAV vectors. The shortened 
version of RPGR ORF15, by being both functional and more stable, will reduce the chances 
of gene rearrangements and the ensuing production of aberrant, frame shifted protein 
products, which are presumed to be deleterious to the photoreceptors. This in principle 
should enhance the margin of safety of the therapy. Miniaturized versions of large genes 
almost invariably come at a substantial cost in terms of compromised functions. This 
downside does not appear to apply to the shortened versions (both mouse and human) of 
RPGR ORF15, based on the in vivo studies that we have conducted. Thus the long version 
of RPGR ORF15 presented in this study, with of its repetitive region removed for added 
stability, could serve as a viable alternative to the “full-length” RPGR ORF15 in 
replacement gene therapies.
Materials and Methods
Animals
The generation and analysis of Rpgr−/− mice have been described previously (Hong and 
others, 2000). The (C57BL/6) Rpgr−/− mice used in this study were bred from backcrossing 
and sibling mating and were maintained in our institutional animal facility. WT mice used in 
the study were C57BL from Charles River Laboratory (Wilmington, MA). Mice were 
maintained under 12hr light/12hr dark lighting cycle. All mice were euthanized by CO2 
inhalation for collection of ocular tissues. The studies were done in accordance with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and approved 
by the IACUC of the Massachusetts Eye and Ear Infirmary.
Plasmid construction and production of recombinant AAV8
Human RPGR ORF 15 cDNA was amplified from human retinal cDNA by PCR using 
primers designed to encompass the entire RPGR ORF15 isoform coding region. No full-
length ORF15 cDNAs were obtained despite repeated attempts using a variety of methods, 
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consistent with the experience of other investigators and that of our own 19. Instead, we 
obtained an abbreviated ORF15 cDNA containing a large 314 codon (942 bp) in-frame 
deletion in the ORF15 exon (2,517-bp remaining) with the bulk of the purine rich repetitive 
region removed (codons 696-1010del, “short form”) (Fig. 1A). A second ORF15 cDNA was 
constructed through recombinant DNA manipulation that contained a 126-codon (378 bp) 
in-frame deletion within the highly repetitive region of exon 15 (with 3,081-bp remaining in 
the ORF15 exon) (codons 862-988del,“long form”). These ORF15 cDNAs were sequenced 
to verify fidelity. To construct the AAV vectors, RPGR cDNAs were inserted into the 
multiple cloning site of the parental pAAV-RK-zsGreen vector. The resulting pAAV-RK-
ORF15-L and pAAV-RK-ORF15-S vectors were packaged into AAV8. AAV2/8 pseudotyped 
vector was generated by tripartite transfection: (1) AAV vector plasmid encoding the gene of 
interest, (2) AAV helper plasmid pLT-RC03 encoding AAV Rep proteins from serotype 2 
and Cap proteins from serotype 8, and (3) adenovirus helper miniplasmid pHGTI-Adeno1) 
into 293A cells. The transfection was performed using a protocol developed by Xiao and co-
workers 45. Two days after transfection, cells were lysed by repeated freeze and thaw cycles. 
After initial clearing of cell debris, the nucleic acid component of the virus producer cells 
was removed by Benzonase treatment. The recombinant AAV vector particles were purified 
by iodixanol density gradient. The purified vector particles were dialyzed extensively against 
PBS and tittered by dot blot hybridization. The purified vectors are referred to as AAV- 
ORF15-L and AAV- ORF15-L in the remainder of the text.
Subretinal injections
Mice were placed under general anaesthesia with an intraperitoneal injection of ketamine 
(90 mg/kg)/xylazine (9 mg/kg). A 0.5% proparacaine solution was applied to the cornea as a 
topical anesthetic. Pupils were dilated with topical application of cyclopentolate and 
phenylephrine hydrochloride. Under an ophthalmic surgical microscope, a small incision 
was made through the cornea adjacent to the limbus using an 18-gauge needle. A 33-gauge 
blunt needle fitted to a Hamilton syringe was inserted through the incision behind the lens 
and pushed through the retina. Injections were made subretinally within the nasal quadrant 
of the retina. Each eye received either 2 × 109 vector genome (AAV- ORF15-L) or 5 × 109 
vector genome (AAV- ORF15-S) in a 1 μl volume. RPGR-ORF15 vectors were administered 
to the left eye (OS, oculus sinister) and control vector (AAV8-RK- EGFP) were 
administered to the right eye (OD, oculus dexter). These are referred throughout this text as 
“treated” or “control”, respectively. Visualization during injection was aided by the addition 
of fluorescein (100mg/ml AK-FLUOR, Alcon, Inc.) to the vector suspensions at 0.1% by 
volume. Fundus examination following the injection showed > 50% of the retina detached in 
most cases, confirming successful subretinal delivery. Cohorts of mice (n=50 total) were 
injected at 1 month of age for protein expression studies and at 3 to 7 months of age (since 
ERGs remained normal during this age period) for functional (ERG) and histological 
studies, prior to major photoreceptor loss.
Histology and immunofluorescence
For light microscopy, enucleated eyes were fixed for 10 minutes in 1% formaldehyde, 2.5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH7.5). Following removal of the anterior 
segments and lenses, the eyecups were left in the same fixative at 4°C overnight. Eyecups 
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were washed with buffer, post-fixed in osmium tetroxide, dehydrated through a graded 
alcohol series and embedded in Epon. Semi-thin sections (1 μm) were cut for light 
microscopy observations. For EM, ultrathin sections were stained in uranyl acetate and lead 
citrate before viewing on a JEOL 100CX electron microscope.
For immunofluorescence staining of ciliary proteins two methods were used. In one method, 
which yielded the strongest fluorescence signal, eyes were enucleated, shock frozen, and 
sectioned at 10-μm thickness in a cryostat. Unfixed frozen sections were then collected on 
glass and stained. In a second method, floating retinal sections were collected and stained. 
For this process eyes were placed in fixative (2% formaldehyde/PBS) and their anterior 
segments and lenses were removed. Duration of fixation was typically 20 minutes. The fixed 
tissues were soaked in 30% sucrose/PBS for at least 2 hours, shock frozen and sectioned 
similar to unfixed tissues. Sections were then collected into PBS buffer and remained free 
floating for the duration of the immunostaining process. For immunostaining of all other 
proteins only floating sections were collected and stained. Stained sections were viewed and 
photographed on a laser scanning confocal microscope (model TCS SP2; Leica). Antibodies 
used were mouse RPGR (S1), a human RPGR C-terminal antibody, anti-rootletin, 1D4 (anti-
rhodopsin), mixed blue/green cone anti-opsin, and Hoechst 33342, nuclear dye stain.
Immunoblotting analysis
Retinal tissues were homogenized in RIPA buffer, boiled in Laemmli buffer and loaded at 15 
μg/lane on 5% SDS-PAGE gels. After gel separation, proteins were blotted to PVDF 
membrane by electrotransfer. The membranes were blocked with 5% non-fat milk and 
incubated with primary antibodies overnight at room temperature. After washing, 
membranes were incubated with peroxidase-conjugated secondary antibodies. SuperSignal® 
West Pico Chemiluminescent Substrate (Pierce) was used for detection. For normalization, 
protein samples were separated on standard SDS-PAGE and probed with a transducin α 
antibody (gift of Dr. Heidi Hamm, Vanderbilt University).
ERG recording
Mice were dark-adapted overnight and anesthetized with sodium pentobarbital injected 
intraperitoneally prior to testing. Both pupils of each animal were topically dilated with 
phenylephrine hydrochloride and cyclopentolate hydrochloride, and mice were then placed 
on a heated platform. Rod dominated responses were elicited in the dark with 10-μs flashes 
of white light (1.37 cd•s /m2) presented at intervals of 1 minute in a Ganzfeld dome. Light-
adapted, cone responses were elicited with the same flashes presented at intervals of 1 Hz in 
the presence of a 41 cd/m2 rod-desensitizing white background. ERGs were monitored 
simultaneously from both eyes with a silver wire loop electrode in contact with each cornea 
topically anesthetized with proparacaine hydrochloride and wetted with Goniosol, with a 
subdermal electrode in the neck as the reference; an electrically-shielded chamber served as 
ground.
All responses were differentially amplified at a gain of 1,000 (−3db at 2 Hz and 300 Hz; 
AM502, Tektronix Instruments, Beaverton, OR), digitized at 16-bit resolution with an 
adjustable peak-to-peak input amplitude (PCI-6251, National Instruments, Austin, TX), and 
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displayed on a personal computer using custom software (Labview, version 8.2, National 
Instruments). Independently for each eye, cone responses were conditioned by a 60 Hz notch 
filter and an adjustable artifact-reject window, summed (n=4-20), and then fitted to a cubic 
spline function with variable stiffness to improve signal:noise without affecting their 
temporal characteristics; in this way we could resolve cone b-wave responses as small as 2 
μV.
Statistical analyses
ERG amplitudes were converted to natural logarithms to better approximate normal 
distributions. JMP Pro, version 11 (SAS Institute, Cary, NC) was used to compare cross-
sectional ERG amplitudes and implicit times based on interocular difference scores, which 
were normally distributed by the Shapiro-Wilks W Goodness of Fit test. JMP Pro with 
Dunnett's method was used to compare RPGR expression divided by rootletin expression 
between wt mice (as control), mice injected with the short construct, and mice injected with 
the long construct; these ratio data were normally distributed. Repeated – measures 
regression with PROC MIXED OF SAS, version 9.3 (SAS Institute) or JMP Pro were used 
to compare ONL thicknesses and inner segment/outer segment lengths for treated versus 
untreated eyes at two ages. When these histologic data departed from normality, they were 
converted to normalized ranks by the Van der Waerden transformation and the regression 
analyses repeated. Repeated-measures regression was also used to compare rates of change 
of ERG amplitude over follow-up by eye. Using log data allowed these longitudinal ERG 
amplitudes to be fitted to a linear model consistent with the published exponential loss of 
ERG amplitude over time in mice with hereditary retinal degenerations46.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
(A) Maps of the native human RPGR ORF15 coding region and both shortened forms of 
AAV-delivered human ORF15cDNA. (B) Immunoblots for the two recombinant forms of 
human RPGR-ORF15. AAV delivery of the small-deletion human cDNA (AAV-ORF15-L, 
“long form”) leads to expression of a human RPGR-ORF15 protein of ~ 160 kD in size. 
AAV delivery of the large-deletion human cDNA (AAV-ORF15-S, “short form”) leads to 
expression of a protein of ~130 kD in size. Both forms of human RPGR-ORF15 protein are 
smaller than endogenous human RPGR ORF15 found in human retinal tissue (~ 200 kD).
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Figure 2. 
RPGR ORF15 expression in Rpgr−/− mouse retinas following subretinal delivery of AAV-
RPGR ORF15. (A) Fluorescence images of both the short (ORF15-S) and long (ORF15- L) 
forms of human RPGR ORF15 protein expression superimposed on Nomarski images to 
illustrate the layers of the outer retina. Staining of unfixed frozen retinal sections was 
performed at 3 weeks following treatment at 1-2 months of age. (B) Fluorescence images of 
both forms of human RPGR ORF15 co-localized with rootletin. Similar to WT, both forms 
of human RPGR ORF15 correctly localized to the photoreceptor connecting cilium just 
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distal to rootletin. RPE, retinal pigment epithelium; OS, outer segment; CC (TZ), connecting 
cilium (transition zone); IS, inner segment; ONL, outer nuclear layer. (C) Ratio of hRPGR 
fluorescent particles to fluorescent rootletin fibers at the connecting cilium for Rpgr −/− eyes 
(n=3) treated with ORF15-S, Rpgr −/− eyes (n=3) treated with ORF15-L, and wt eyes (n=3). 
Counts were obtained for both rootletin within the inner segment and RPGR just distal to 
rootletin over a 100μm length of midperipheral retina. Values are means ± 1 standard error). 
(D) Expression pattern of short and long form ORF15 protein in fixed floating retinal 
sections of Rpgr−/− mice. Sections were stained for human RPGR ORF15 protein 
localization 4-6 weeks following treatment at 2-3 months of age. In wt retina, murine RPGR 
ORF15 protein is seen as a discrete green fluorescent signal (dots) occupying the region 
between the photoreceptor inner and outer segments, at the level of the transition zone or 
connecting cilium. In contrast, the fluorescent signal for the short form of ORF15 (AAV-
ORF15-S) is not limited to level of the photoreceptor connecting cilium but is also seen as 
diffuse signal throughout the inner and outer segments as well. The fluorescent signal for the 
long form of ORF15 shows very little, if any mislocalization, and is largely limited to the 
connecting cilium region similar to wt. OS, outer segment; CC (TZ), connecting cilium 
(transition zone); IS, inner segment; ONL, outer nuclear layer.
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Figure 3. 
Immunohistochemical (yellow) analyses of rod and cone photoreceptors in treated (short and 
long form of ORF15) and control Rpgr−/− mouse retinas at age 13 months (6-months post 
injection). In the Rpgr−/− mouse retina treated with the short form of ORF15 (AAV-ORF15-
S), rhodopsin and cone opsin (mixed S & M cones in the inferior retina) mislocalization 
staining patterns are virtually indistinguishable from those seen in the control retina. Note 
the cone opsin mislocalization in the inner segments and synaptic layer in both of these 
mouse retinas.Similarly, rod and cone outer segments are shortened and disorganized with a 
reduced outer nuclear layer compared to an age matched wt retina. In contrast, in the 
Rpgr−/− mouse retina treated with the long form of ORF15 (AAV-ORF15-L) rhodopsin 
shows outer segment partitioning similar to WT mouse retina. Also in the ORF15 long form 
treated retina rod outer segments are longer and well organized and the ONL is thicker 
compared with the control retina. Cone opsin staining shows more numerous cone 
photoreceptors with elongated and well-organized outer segments in the ORF15 long form 
treated Rpgr−/− mouse retina compared with control.
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Figure 4. 
Rescue of photoreceptor cells following treatment with RPGR ORF15-L in Rpgr−/− mice. 
(A) Shown are stacked bar graphs for ONL thickness (top) and IS/OS length (bottom) for 
treated (red) and fellow control (blue) eyes in 3 mice at 18 months of age. (B) 
Representative light micrographs from a WT mouse and an ORF15-L treated and fellow 
control eye from an Rpgr−/− mouse at 18 months of age. Images were taken from the mid 
periphery along the vertical meridian in the superior retina,
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Figure 5. 
(A) Rod a-wave, rod b-wave, and cone b-wave amplitudes from 16 Rpgr−/− mice at 11-14 
months of age following treatment with RPGR ORF15-L. Control eyes (OD) showed 
disproportionate loss of cone b-wave amplitude relative to rod b-wave amplitude compared 
with the lower limits for wild-type mice. Mean values for all three measures were 
significantly different between eyes (p<0.001). (B) Scatterplots of ERG amplitude for 22 
Rpgr−/− mice between 9 and 18 months of age on a log scale for the dark-adapted (rod) b-
wave (upper graph) and light-adapted (cone) b-wave (lower graph) following treatment with 
RPGR ORF15-L. Data points have been shifted slightly horizontally for each age group to 
minimize data overlap. The regression lines for treated and control eyes were fitted by 
repeated measures longitudinal regression using PROC Mixed of SAS based on all available 
data. (C) Representative dark-adapted (DA) and light-adapted (LA) ERG waveforms from a 
pair of ORF15-L treated and fellow control Rpgr−/− eyes at 18 months of age. WT (age-
matched) ERG waveforms are shown for comparison. ERG a-wave and b-wave are labeled a 
and b, respectively.
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